Oct 8, 2026 06:35PM
Oct 8, 2026 06:35PM
Oct 6, 2026 06:56AM
Oct 5, 2026 06:50AM
Sep 9, 2026 07:27AM
Sep 8, 2026 06:50AM
Sep 8, 2026 06:50AM Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Sep 3, 2026 06:51AM
Sep 3, 2026 06:50AM
Aug 14, 2026 06:46AM
Aug 13, 2026 04:04AM
Aug 12, 2026 06:50AM
Aug 6, 2026 06:51AM
Aug 6, 2026 06:50AM Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Jul 22, 2026 06:50AM
Jul 22, 2026 06:50AM
Jul 22, 2026 06:50AM
Jul 15, 2026 05:11AM
Jul 6, 2026 06:50AM
Jul 6, 2026 06:50AM
Jun 15, 2026 06:50AM Pharvaris presents data on deucrictibant for hereditary angioedema treatment
Jun 15, 2026 06:50AM
May 12, 2026 04:05PM
May 8, 2026 06:01AM
May 8, 2026 06:00AM
Apr 20, 2026 06:50AM
Apr 20, 2026 06:50AM
Apr 2, 2026 06:50AM Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 20, 2026 06:51AM
Mar 20, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 2, 2026 06:55AM
Mar 2, 2026 06:50AM Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Jan 12, 2026 06:50AM
Jan 12, 2026 06:50AM
Dec 3, 2025 06:50AM
Dec 3, 2025 06:50AM
Nov 12, 2025 06:50AM
Nov 10, 2025 06:50AM
Aug 12, 2025 04:05PM Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 10, 2025 06:51AM
Jul 10, 2025 06:50AM
Jun 16, 2025 06:50AM
Jun 16, 2025 06:50AM
Jun 2, 2025 06:52AM
Jun 2, 2025 06:50AM
May 13, 2025 04:05PM Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 7, 2025 06:58AM

334,270 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All